Biology subjects

Leow, A.

Publications and source records attributed to Leow, A..

4 recordsLinked to original sources

bioRxiv2023

Disrupted excitation-inhibition balance in cognitively normal individuals at risk of Alzheimers disease

BackgroundSex differences impact Alzheimers disease (AD) neuropathology, but cell-to-network level dysfunctions in the prodromal phase are unclear. Alterations in hippocampal excitation-inhibition balance (EIB) have recently been linked to early AD pathology. ObjectiveExamine how AD risk factors (age, APOE-{varepsilon}4, amyloid-{beta}) relate to hippocampal EIB in cognitively normal males and females using connectome-level measures. MethodsIndividuals from the OASIS-3 cohort (age 42-95) were studied (N = 437), with a subset aged 65+ undergoing neuropsychological testing (N = 231). ResultsIn absence of AD risk factors (APOE-{varepsilon}4/A{beta}+), whole-brain EIB decreases with age more significantly in males than females (p = 0.021, {beta} = -0.007). Regression modeling including APOE-{varepsilon}4 allele carriers (A{beta}-) yielded a significant positive AGE-by-APOE interaction in the right hippocampus for females only (p = 0.013, {beta} = 0.014), persisting with inclusion of A{beta}+ individuals (p = 0.012, {beta} = 0.014). Partial correlation analyses of neuropsychological testing showed significant associations with EIB in females: positive correlations between right hippocampal EIB with categorical fluency and whole-brain EIB with the trail-making test (p < 0.05). ConclusionSex differences in EIB emerge during normal aging and progresses differently with AD risk. Results suggest APOE-{varepsilon}4 disrupts hippocampal balance more than amyloid in females. Increased excitation correlates positively with neuropsychological performance in the female group, suggesting a duality in terms of potential beneficial effects prior to cognitive impairment. This underscores the translational relevance of APOE-{varepsilon}4 related hyperexcitation in females, potentially informing therapeutic targets or early interventions to mitigate AD progression in this vulnerable population.

neuroscience↗

bioRxiv2023

Enhanced simulations of whole-brain dynamics using hybrid resting-state structural connectomes

The human brain, composed of billions of neurons and synaptic connections, is an intricate network coordinating a sophisticated balance of excitatory and inhibitory activity between brain regions. The dynamical balance between excitation and inhibition is vital for adjusting neural input/output relationships in cortical networks and regulating the dynamic range of their responses to stimuli. To infer this balance using connectomics, we recently introduced a computational framework based on the Ising model, first developed to explain phase transitions in ferromagnets, and proposed a novel hybrid resting-state structural connectome (rsSC). Here, we show that a generative model based on the Kuramoto phase oscillator can be used to simulate static and dynamic functional connectomes (FC) with rsSC as the coupling weight coefficients, such that the simulated FC well aligns with the observed FC when compared to that simulated with traditional structural connectome. Simulations were performed using the open source framework The Virtual Brain on High Performance Computing infrastructure.

neuroscience↗

bioRxiv2020

Potential depression and antidepressant-response biomarkers in human lymphoblast cell lines from treatment-responsive and treatment-resistant subjects: roles of SSRIs and omega-3 polyunsaturated fatty acids

While several therapeutic strategies exist for depression, most antidepressant drugs require several weeks before reaching full biochemical efficacy and remission is not entirely achieved in many patients. Therefore, biomarkers for depression and drug-response would help tailor treatment strategies. This study made use of banked human lymphoblast cell lines (LCLs) from normal and depressed subjects; the latter divided into remitters and non-remitters. Due to the fact that previous studies have shown effects on growth factors, cytokines and elements of the cAMP generating system as potential biomarkers for depression and antidepressant action, these were examined in LCLs. Initial gene and protein expression profiles for signaling cascades related to neuroendocrine and inflammatory functions differ among the three groups. Growth factor genes, including VEGFA and BDNF were significantly down-regulated in cells from depressed subjects. In addition, omega-3 polyunsaturated fatty acids (n-3 PUFAs) have been reported to act as both antidepressants and anti-inflammatories, but the mechanisms for these effects are not established. Here we showed that n-3 PUFAs and escitalopram (selective serotonin reuptake inhibitors, SSRIs) treatment increased adenylyl cyclase (AC) and BDNF gene expression in LCLs. These data are consistent with clinical observations showing that n-3 PUFA and SSRI have antidepressant affects, which may be additive. Contrary to observations made in neuronal and glial cells, n-3 PUFA treatment attenuated cAMP accumulation in LCLs. However, while lymphoblasts show paradoxical responses to neurons and glia, patient-derived lymphoblasts appear to carry potential depression biomarkers making them an important tool for studying precision medicine in depressive patients. Furthermore, these data validate usefulness of n-3 PUFAs in treatment for depression.

neuroscience↗

bioRxiv2019

Differential expression of glutamate transporters and monoaminergic genes in major depression and suicide.

Accumulating evidence indicates that the glutamate and monoamine systems contribute to the pathophysiology of major depressive disorder (MDD) and suicide. We have tested the expression of genes encoding glutamate transporters and monoaminergic proteins in the dorsolateral prefrontal cortex (DLPFC) of MDD subjects who died by suicide (MDD-S, n=51), MDD non-suicide subjects (MDD-NS, n=28), and non-psychiatric controls (CTRL, n=32). We analyzed glutamate transporters (EAAT1, EAAT2, VGLUT1, and VGLUT2) and monoaminergic genes (SERT, NET, DAT, PMAT, VMAT, TPH1 and TPH2). Females but not males with MDD showed higher expression of all glutamate transporters relative to CTRLs (P<0.05). MDD-S groups of both sexes had higher VGLUT2 expression (P<0.05). MDD-S females who were antidepressant positive (+) had lower EAAT1 expression (P=0.004), perhaps indicating poor treatment response. Analyses of monoaminergic genes revealed lower VMAT1 expression (P=0.002) in MDD males, and conversely higher VMAT2 in MDD females (P=0.004). MDD females also had higher VMAT2, TPH2 and NET expression (p<0.05), and in contrast, MDD males had lower VMAT1 and PMAT expression. Therefore, we report sex differences in the expression of glutamate transporters and some monoaminergic genes in the DLPFC in MDD. Most of these findings are novel, but lower EAAT1 expression in MDD-S replicates previous studies. Lower EAAT1 expression coupled with higher VGLUT2 expression in MDD-S may lead to increased synaptic glutamate, neuronal loss and glial loss in the DLPFC in MDD and suicide reported previously. These deficits may contribute to lower DLPFC activity, poor problem solving and impaired executive function exhibited in severe depression and suicide.

pharmacology and toxicology↗